Keapstone Therapeutics launched in world-first partnership to develop new drugs for Parkinson’s

The University of Sheffield and Parkinson’s UK have launched a new £1million virtual biotech company in the next stage[1] of a pioneering research programme to create new drugs for Parkinson’s.

In a partnership that is the first of its kind, Keapstone Therapeutics will combine world-leading research from the University with funding and expertise from the charity to help develop revolutionary drugs for Parkinson’s, which affects around 127,000 people in the UK.

Although similar partnerships between charities and research specialists have been formed in the past, this is the first time a charity has directly approached researchers to launch a spin-out company with the aim of advancing one particular research programme.

The creation of Keapstone Therapeutics is part of Parkinson’s UK’s new Virtual Biotech venture, formed to combat the lost opportunities in drug discovery and early clinical development caused by the changing pharma landscape. It allows the charity to work virtually – providing leadership and critical funding, in partnership with a range of other organisations that have the facilities and staff to carry out scientific work on a contract basis.

Keapstone is the first ‘single-asset’ spin-out company to be created in this way and it ensures that, if successful, the research is in the best possible position to receive investment – allowing immediate progress towards clinical trials. The structure of the set-up also means that Parkinson’s UK and The University of Sheffield will each retain a stake in any future developments.

Director of Research at Parkinson’s UK, Arthur Roach, said: “Due to the funding gap in early stage drug discovery, there are promising scientific breakthroughs for Parkinson’s happening every day that are not being picked up and developed by commercial companies.

“This major new programme of work will allow us to act in a similar way to a small biotech company. However, unlike a commercial company, our primary goal is the creation of new treatments to improve the lives of people with Parkinson’s, regardless of commercial considerations.

“Keapstone is our first step in this pioneering programme and it is a world-first in terms of its formation. By seeking early collaboration with a University in the creation of a spin-out biotech company, we will be able to investigate and develop potential Parkinson’s treatments with an intensity that is unprecedented for a charity.”

Keapstone Therapeutics will build on over a decade of research at the University’s Sheffield Institute for Translational Neuroscience (SITraN), where researchers have pinpointed a way to trigger a possible in-built defence system that helps protect brain cells from oxidative stress. This stress is caused by a damaging build-up of free-radicals and is found in the brain cells of people with Parkinson’s.

Dr Richard Mead, of SITraN, discovered a new class of compounds that can activate the brain cell defence system. Keapstone Therapeutics will now fund the chemistry specialists, Sygnature Discovery, to further develop these molecules, which could eventually become new drugs that can slow or stop the progression of Parkinson’s.

Dr Richard Mead said: “We are very excited about this new partnership with Parkinson’s UK. It is a great opportunity for us to pursue a novel drug discovery program for Parkinson’s and other neurodegenerative conditions, such as motor neuron disease (MND). We will now progress these molecules through the next stage of drug development.”

Professor Pamela Shaw, Director of SITraN said: “We are very excited to have the opportunity to further our programme of work to develop new approaches for protecting neurons and slowing disease progression in Parkinson’s disease and MND, by designing drugs which boost the internal cellular defence mechanisms. Along with Parkinson’s UK, Keapstone Therapeutics will facilitate a step-change in the drug development programme emerging from the scientific and pre-clinical research within SITraN”.

Steve Ford, Chief Executive at Parkinson’s UK, said: “Parkinsons’s UK is delighted to be working with Sheffield University through the formation of Keapstone, to help unlock the potential of the very promising discoveries made by Dr Richard Mead and his team.

“For years we have worked to support and accelerate the progression of research discoveries from the lab into clinical trials, with the aim of developing new drugs that can be used to manage and treat Parkinson’s. The launch of Keapstone marks an exciting step change in our strategy, which will allow us greater involvement in research and more flexibility to progress promising leads.

“This extraordinary venture would not have been possible without our supporters and partners - and we’re looking forward to sharing the developments of this new project with them.”

For more information about Keapstone Therapeutics please visit For more information about Parkinson’s UK’s virtual biotech programme please visit

[1] This next stage of research will further a project initiated by the University’s Sheffield Institute for Translational Neuroscience (SITraN), in collaboration with drug discovery platform, European Lead Factory.


Notes to editors

About Parkinson’s

Every hour, someone in the UK is told they have Parkinson's.

It affects 127,000 people in the UK - which is around one in 500 of the population, making it the second most common neurodegenerative condition after Alzheimer's.

Parkinson's is a progressive neurological condition caused by the unexplained death of brain cells that create a chemical called dopamine. Without dopamine people experience slowness of movement, rigidity and a tremor. As well as affecting movement, people with Parkinson's can find that other issues, such as tiredness, pain, depression and constipation, can have an impact on their day-to-day lives.

This year is the 200th anniversary of James Parkinson’s Essay on the Shaking Palsy, which first recognised the condition. Although medication that can treat the symptoms of Parkinson’s have been developed over time, there has still been no treatment shown to reverse the effects of Parkinson’s or slow its progression. There is no known cure.

Parkinson's UK is the UK's leading charity supporting those with the condition. Its mission is to find a cure and improve life for everyone affected by Parkinson's through cutting edge research, information, support and campaigning.

For advice, information and support, visit or call our free, confidential helpline on 0808 800 0303.

For more information please contact: Kirsty Callingham, Senior Media and PR Officer, Parkinson’s UK, 020 7932 9311,

Out of hours: 07961 460248

The University of Sheffield

With almost 27,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.

A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2016 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

For further information, please visit

For further information please contact: Amy Pullan, Media Relations Officer, University of Sheffield, 0114 222 9859,

To read other news releases about the University of Sheffield, visit

[1] This next stage of research will further a project initiated by the University’s Sheffield Institute for Translational Neuroscience (SITraN), in collaboration with drug discovery platform, European Lead Factory.